1-9 of 9
Anastasios Stathis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas, Eugenio Gaudio, Chiara Tarantelli, Afua A. Mensah, Filippo Spriano, Antonella Zucchetto, Francesca M. Rossi, Andrea Rinaldi, Manuel Castro de Moura, Sandra Jovic, Roberta Bordone Pittau, Anastasios Stathis, Georg Stussi, Valter Gattei, Jennifer R. Brown, Manel Esteller, Emanuele Zucca, Davide Rossi, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 368–380.
https://doi.org/10.1158/1535-7163.MCT-23-0068
Published: 04 March 2024
View articletitled, ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Open the PDF for ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms in another window
Includes: Supplementary data
Journal Articles

Abstract C139: The IRAK4 inhibitor emavusertib (CA-4948) synergizes with second generation BTK inhibitors acalabrutinib and zanubrutinib in MYD88-L265P mutated lymphoma cell lines

Francesca Guidetti, Alberto J. Arribas, Eleonora Cannas, Emanuele Zucca, Anastasios Stathis, Reinhard von Roemeling, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C139.
https://doi.org/10.1158/1535-7163.TARG-23-C139
Published: 01 December 2023
View articletitled, Abstract C139: The IRAK4 inhibitor emavusertib (CA-4948) synergizes with second generation BTK inhibitors acalabrutinib and zanubrutinib in MYD88-L265P mutated lymphoma cell lines
Journal Articles

Abstract B165: A pharmacologic screen identifies drugs to be combined with the non-ATP competitive PI3Kδ inhibitor roginolisib (IOA-244) for an improved anti-tumor activity in lymphoma models

Chiara Tarantelli, Elisa Civanelli, Eleonora Cannas, Filippo Spriano, Afua A. Mensah, Luciano Cascione, Alberto J Arribas, Anastasios Stathis, Karolina Niewola-Staszkowska, Giusy Di Conza, Michael Lahn, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B165.
https://doi.org/10.1158/1535-7163.TARG-23-B165
Published: 01 December 2023
View articletitled, Abstract B165: A pharmacologic screen identifies drugs to be combined with the non-ATP competitive PI3Kδ inhibitor roginolisib (IOA-244) for an improved anti-tumor activity in lymphoma models
Journal Articles

Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma

Alberto J. Arribas, Sara Napoli, Eugenio Gaudio, Luciano Cascione, Alessandra Di Veroli, Chiara Tarantelli, Filipppo Spriano, Antonella Zucchetto, Francesca Rossi, Giulio Sartori, Andrea Rinaldi, Anastasios Stathis, Georg Stussi, Valter Gattei, Gabriele Cruciani, Emanuele Zucca, Davide Rossi, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A127.
https://doi.org/10.1158/1535-7163.TARG-19-A127
Published: 01 December 2019
View articletitled, Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma
Journal Articles

Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103

Filippo Spriano, Chiara Tarantelli, Alberto Arribas, Eugenio Gaudio, Luciano Cascione, Luca Aresu, Emanuele Zucca, Davide Rossi, Anastasios Stathis, Maximilien Murone, Dirk Weber, Rajwinder Lehal, Freddy Radtke, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B061.
https://doi.org/10.1158/1535-7163.TARG-17-B061
Published: 01 January 2018
View articletitled, Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103
Journal Articles

Abstract A179: The BRD4 degrader MZ1 exhibits potent antitumoral activity in diffuse large B cell lymphoma of the activated B cell-like type

Chiara Tarantelli, Hillarie Ekeh, Carmelo Moscatello, Eugenio Gaudio, Andrea Testa, Emanuele Zucca, Anastasios Stathis, Alessio Ciulli, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A179.
https://doi.org/10.1158/1535-7163.TARG-17-A179
Published: 01 January 2018
View articletitled, Abstract A179: The BRD4 degrader MZ1 exhibits potent antitumoral activity in diffuse large B cell lymphoma of the activated B cell-like type
Journal Articles

Abstract B76: Evaluation of the novel BET Bromodomain inhibitor BAY 1238097 in lymphoma models identifies EZH2 and MYD88 mutations as potential biomarkers and the bases for combinations

Elena Bernasconi, Eugenio Gaudio, Chiara Tarantelli, Luciano Cascione, Ivo Kwee, Andrea Rinaldi, Afua A. Mensah, Anastasios Stathis, Matthias Ocker, Emanuele Zucca, Bernard Haendler, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B76.
https://doi.org/10.1158/1535-7163.TARG-15-B76
Published: 01 December 2015
View articletitled, Abstract B76: Evaluation of the novel BET Bromodomain inhibitor BAY 1238097 in lymphoma models identifies EZH2 and MYD88 mutations as potential biomarkers and the bases for combinations
Journal Articles

Abstract A129: Novel histone deacetylase inhibitors ITF-A and ITF-B exhibit efficacy in preclinical models of mature B-cell lymphomas.

Afua A. Mensah, Eugenio Gaudio, Ivo Kwee, Andrea Rinaldi, Gianluca Fossati, Anastasios Stathis, Emanuele Zucca, Gianluca Caprini, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A129.
https://doi.org/10.1158/1535-7163.TARG-13-A129
Published: 01 November 2013
View articletitled, Abstract A129: Novel histone deacetylase inhibitors ITF-A and ITF-B exhibit efficacy in preclinical models of mature B-cell lymphomas.
Journal Articles

Abstract A119: The BET-bromodomain inhibitor OTX015 shows synergism with several anticancer agents in preclinical models of diffuse large B-cell lymphoma (DLBCL).

Eugenio Gaudio, Ivo Kwee, Elena Bernasconi, Andrea Rinaldi, Monica Testoni, Michela Boi, Anastasios Stathis, Eugenia Riveiro, Kay Noel, Emanuele Zucca, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A119.
https://doi.org/10.1158/1535-7163.TARG-13-A119
Published: 01 November 2013
View articletitled, Abstract A119: The BET-bromodomain inhibitor OTX015 shows synergism with several anticancer agents in preclinical models of diffuse large B-cell lymphoma (DLBCL).